| Literature DB >> 29351847 |
Lixin Wan1, Kexin Xu2, Yongkun Wei3, Jinfang Zhang4, Tao Han5, Christopher Fry6, Zhao Zhang7, Yao Vickie Wang7, Liyu Huang8, Min Yuan9, Weiya Xia3, Wei-Chao Chang10, Wen-Chien Huang11, Chien-Liang Liu11, Yuan-Ching Chang11, Jinsong Liu12, Yun Wu12, Victor X Jin7, Xiangpeng Dai4, Jianfeng Guo13, Jia Liu14, Shulong Jiang15, Jin Li16, John M Asara9, Myles Brown17, Mien-Chie Hung18, Wenyi Wei19.
Abstract
Sustained energy starvation leads to activation of AMP-activated protein kinase (AMPK), which coordinates energy status with numerous cellular processes including metabolism, protein synthesis, and autophagy. Here, we report that AMPK phosphorylates the histone methyltransferase EZH2 at T311 to disrupt the interaction between EZH2 and SUZ12, another core component of the polycomb repressive complex 2 (PRC2), leading to attenuated PRC2-dependent methylation of histone H3 at Lys27. As such, PRC2 target genes, many of which are known tumor suppressors, were upregulated upon T311-EZH2 phosphorylation, which suppressed tumor cell growth both in cell culture and mouse xenografts. Pathologically, immunohistochemical analyses uncovered a positive correlation between AMPK activity and pT311-EZH2, and higher pT311-EZH2 correlates with better survival in both ovarian and breast cancer patients. Our finding suggests that AMPK agonists might be promising sensitizers for EZH2-targeting cancer therapies.Entities:
Keywords: AMPK; EZH2; metformin; ovarian cancer; phosphorylation; polycomb repressive complex 2
Mesh:
Substances:
Year: 2018 PMID: 29351847 PMCID: PMC5777296 DOI: 10.1016/j.molcel.2017.12.024
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970